HI SB190

Excludes apomorphine, thebaine-derived butorphanol, dextrorphan, nalbuphine, nalmefene, naloxegol, naloxone, and naltrexone from Schedule I narcotic drug classifications under Hawaii's controlled substances act.

Allows qualified individual practitioners to administer, dispense, and prescribe any Schedule II, III, IV, or V narcotic drug approved by the FDA for medically-managed withdrawal treatment (detoxification or maintenance treatment), provided they comply with federal regulations and state registration requirements.

Permits physicians not specifically registered for narcotic treatment programs to administer (but not prescribe) narcotic drugs for acute withdrawal symptom relief while arranging referral for treatment, limited to one day of medication at a time and no more than three days total.

Clarifies that physicians and hospital staff may administer or dispense narcotic drugs to maintain or detoxify patients as an incidental part of treating medical or surgical conditions other than addiction, or to treat intractable pain.

Effective date: July 1, 2017.